Search Results for “vaccine” – Page 19 – media

UK monkeypox vaccine rollout to wind down

The UK Health Security Agency (UKHSA) has announced its vaccination programme against mpox will end this summer. Cases of the disease have fallen from a peak of 350 per week in July to just six new cases so far in 2023, three of which were caught overseas. First doses of the vaccine will remain available to those at highest risk until 16 June, with second doses available until the end of July. The UKHSA says it will monitor cases and restart the programme if needed. While the mpox, formerly known as monkeypox, virus can infect anyone, most UK cases were among men who have sex with men. Anyone eligible who has not yet received a vaccine is being encouraged to book an appointment to protect themselves before summer. Greg Owen, from sexual health and Human Immunodeficiency Virus (HIV) charity the Terrence Higgins Trust, said: ...
- Source: drugdu
- 192
- March 30, 2023
GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate There are currently no licensed vaccines offering simultaneous protection against all five serogroups

GSK has reported positive top-line results from a phase 3 study of its five-in-one meningococcal vaccine candidate, MenABCWY, in healthy individuals aged ten to 25 years. Invasive meningococcal disease (IMD) is an uncommon but serious illness that can cause life-threatening complications or even death, with the highest incidence occurring in children and adolescents. Five Neisseria meningitides serogroups – A, B, C, W, and Y – account for nearly all IMD cases, but there are currently no licensed vaccines that offer simultaneous protection against all of them. In the US, two separate vaccines needing four injections are required to protect against all five serogroups. This regimen, together with low awareness of the disease, can lead to poor immunisation rates, with an estimated coverage of only 31% of adolescents in the US. It is hoped that GSK’s MenABCWY, which combines the antigenic components of its licensed Bexsero (MenB) and Menveo (MenACWY) meningococcal ...
- Source: drugdu
- 156
- March 27, 2023
FT

Pfizer and European Commission officials have waded through months of pushback over a large, controversial COVID-19 vaccine supply deal in Europe. They’ve now reportedly hashed out a new supply agreement—but there’s a catch. Under the terms of a revised deal, Pfizer agreed to extend the European supply contract from 2023 out to 2026, the Financial Times reports based on two people with knowledge of the talks. Given the drop in vaccine use, Pfizer also agreed to cut the total number of doses to be supplied by 40%, but the company is also pushing for payment for the doses that will never be manufactured, according to the publication. Pfizer and the European Commission (EC) inked their large vaccine supply deal in May 2021. The agreement covered 900 million vaccine doses for delivery split between 2022 and 2023, with the option for the EC to order another 900 million doses in the future. In December 2021, European officials exercised part of ...
- Source: drugdu
- 518
- March 24, 2023
Moderna CEO grilled over plan to raise Covid vaccine price at Senate hearing

Stéphane Bancel argued a price increase was necessary because of waning demand and supply chain issues. Moderna CEO Stéphane Bancel defended the company’s plans to raise the price of its Covid vaccine at a Senate hearing Wednesday, saying the move was necessary because its government funding will soon end. “Until now, the U.S. government has purchased and distributed the vaccine. Now Moderna, a small company, must ensure that anyone who wants a vaccine can get one at a location convenient to them,” Bancel told members of the Senate Committee on Health, Education, Labor and Pensions at a hearing titled “Taxpayers Paid Billions For It: So Why Would Moderna Consider Quadrupling the Price of the COVID Vaccine?” The company has said it plans to increase the cost of the vaccine to consumers to $130 a dose from the current price of about $26. The panel’s chair, Sen. Bernie ...
- Source: drugdu
- 139
- March 24, 2023
Pfizer Reports Strong Earnings, Driven by Continued Success of COVID-19 Vaccine

Pfizer, the American pharmaceutical giant, has reported strong earnings for the fourth quarter of 2022, driven by the continued success of its COVID-19 vaccine. The vaccine has been a major growth driver for the company, with sales expected to reach $36 billion in 2023. Pfizer’s revenue for the quarter was $24.6 billion, up 17% from the same period the previous year. Net income was $5.2 billion, an increase of 6% compared to the same quarter in 2021. The strong results were driven by the success of the company’s COVID-19 vaccine, as well as several other key products, including Prevnar 13 and Ibrance. The COVID-19 vaccine, developed in partnership with German company BioNTech, has been a major contributor to Pfizer’s success in 2022. The vaccine has been authorized for emergency use in more than 200 countries and territories around the world, and Pfizer has shipped more than 2 billion ...
- Source: drugdu
- 147
- March 24, 2023
Moderna expects to price its COVID vaccine at about $130 in the US

March 20 (Reuters) – Moderna Inc (MRNA.O) expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday. “There are different customers negotiating different prices right now, which is why it’s a little bit complicated,” Hoge said ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna’s pricing plans. Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc (PFE.N) said in October it was considering for its rival COVID shots sold in partnership with BioNTech (22UAy.DE). Hoge said the government’s Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. That there were two to three times more hospitalizations and deaths ...
- Source: drugdu
- 137
- March 22, 2023
Brazil’s ANVISA approves Takeda’s dengue vaccine Qdenga

Qdenga’s approval is supported by the data obtained from 19 clinical trials, and follows similar decisions in other countries. The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda’s tetravalent dengue virus vaccine, Qdenga. The vaccine, previously known as TAK-003, has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these. Qdenga is purported to be the only dengue vaccine approved in Brazil for use in people without the need for pre-vaccination testing and regardless of previous exposure. ANVISA’s approval follows similar decisions by the European Commission in December, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) last month. The company continues to advance regulatory filings in other dengue-endemic countries in Asia and Latin America. In ...
- Source: drugdu
- 144
- March 17, 2023
Chasing Pfizer, GSK’s 5-in-1 meningococcal vaccine delivers phase 3 trial win

Nearly three years after dosing the first patient in a phase 3 trial, GSK has now reported positive results from the trial of its much-anticipated combination meningitis vaccine. The shot, a combination of GSK’s approved vaccines Bexsero and Menveo, targets meningitis and blood poisoning caused by the A, B, C, W, and Y groups of meningococcal bacteria. The serogroups A, B, C, W and Y cause nearly all invasive meningococcal disease (IMD) cases globally, GSK said in a statement. As it stands now in the U.S., protection from all five groups requires four injections from two separate vaccines. But GSK is looking to change that with its two-dose shot, which is administered six months apart. GSK said that the vaccine candidate met endpoints in the trial, which enrolled healthy people between 10 and 25 years of age. The vaccine matched up to Bexsero and Menveo, eliciting a “clinically meaningful immune response.” https://www.fiercepharma.com/pharma/gsks-combination-menabcwy-vaccine-holds-its-own-against-gsks-approved-meningitis-jabs
- Source: drugdu
- 129
- March 16, 2023
LG Chem locks in $200M vaccine supply deal with UNICEF

Korea’s LG Chem is stepping up to the plate with a deal to manufacture essential vaccines for millions of infants and children. The company has locked up a $200 million deal with the United Nation’s Children’s Fund (UNICEF) to supply both its polio shot Eupolio and its pentavalent vaccine Eupenta, which protects against diphtheria, pertussis, tetanus, hepatitis B and meningitis. The contract is evenly split between supplies of both shots. The $100 million Eupolio contract provides supplies of the shot for the two years from 2024 to 2025, while LG Chem agreed to provide Eupenta for the five-year stretch from 2023 to 2027. The deal is expected to cover vaccines for roughly 80 million kids and infants around the world. LG Chem credited the deal to its investment in a factory in Osong, Korea. The site can produce more than 60 million dodses of Eupolio per year, according to the ...
- Source: drugdu
- 123
- March 16, 2023
Early data shows CanSinoBIO’s inhaled COVID-19 vaccine triggers immune response

CanSinoBIO’s inhaled COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study. The inhaled two-dose candidate is modified from CanSinoBIO’s injected COVID-19 jab Ad5-nCoV vaccine, which is already approved in China and other countries around the world. Results from a Phase I clinical trial, published in The Lancet, found that two-doses of the inhaled Ad5-nCoV vaccine can trigger a similar immune response to a single-dose of the injected version. The inhaled version was also found to trigger neutralising antibodies and T cell responses after one dose. The study also found that the inhaled version of the vaccine did not cause serious side effects, demonstrating an encouraging safety profile in the early-stage trial. A number of drugmakers are also developing inhaled treatments for COVID-19, including Verona Pharma. UK-headquartered Verona announced at the beginning of the year that it had completed enrolment ...
- Source: drugdu
- 972
- September 1, 2021
CanSinoBIO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.